APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026

27 December 2025195 pages

Choose your research edition.

Industry ResearchPneumococcal Polysaccharide Vaccine Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pneumococcal Polysaccharide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumococcal Polysaccharide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumococcal Polysaccharide Vaccine market include Sino Biopharm, Zhifei Biological, Walvax, Merck & Co., Sinovac, Kangtai Bio, Antejin Biotechnology, AIM Bio and Sanofi Pasteur, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Polysaccharide Vaccine Segment by Company

Sino Biopharm

Zhifei Biological

Walvax

Merck & Co.

Sinovac

Kangtai Bio

Antejin Biotechnology

AIM Bio

Sanofi Pasteur

Pfizer

Pneumococcal Polysaccharide Vaccine Segment by Type

PPSV23

PCV13

Others

Pneumococcal Polysaccharide Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pneumococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Polysaccharide Vaccine industry.

Chapter 3: Detailed analysis of Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Polysaccharide Vaccine Industry Trends Table 2. Pneumococcal Polysaccharide Vaccine Industry Drivers Table 3. Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal Polysaccharide Vaccine Industry Restraints Table 5. Global Pneumococcal Polysaccharide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Polysaccharide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Company (Units) & (2021-2026) Table 8. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pneumococcal Polysaccharide Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pneumococcal Polysaccharide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumococcal Polysaccharide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pneumococcal Polysaccharide Vaccine Company, Product Type & Application Table 13. Global Pneumococcal Polysaccharide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PPSV23 Table 18. Significant Companies of PCV13 Table 19. Significant Companies of Others Table 20. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021-2026) & (Units) Table 22. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2027-2032) & (Units) Table 23. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Pneumococcal Polysaccharide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Centers for Disease Control and Prevention Table 32. Significant Companies of Others Table 33. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021-2026) & (Units) Table 35. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2027-2032) & (Units) Table 36. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Pneumococcal Polysaccharide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 44. Global Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (Units) Table 45. Global Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (Units) Table 47. Global Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Pneumococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Pneumococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Pneumococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Pneumococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 56. Global Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 58. Global Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 60. Global Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pneumococcal Polysaccharide Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pneumococcal Polysaccharide Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Sino Biopharm Company Information Table 66. Sino Biopharm Business Overview Table 67. Sino Biopharm Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Sino Biopharm Pneumococcal Polysaccharide Vaccine Product Portfolio Table 69. Sino Biopharm Recent Development Table 70. Zhifei Biological Company Information Table 71. Zhifei Biological Business Overview Table 72. Zhifei Biological Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Zhifei Biological Pneumococcal Polysaccharide Vaccine Product Portfolio Table 74. Zhifei Biological Recent Development Table 75. Walvax Company Information Table 76. Walvax Business Overview Table 77. Walvax Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Walvax Pneumococcal Polysaccharide Vaccine Product Portfolio Table 79. Walvax Recent Development Table 80. Merck & Co. Company Information Table 81. Merck & Co. Business Overview Table 82. Merck & Co. Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Merck & Co. Pneumococcal Polysaccharide Vaccine Product Portfolio Table 84. Merck & Co. Recent Development Table 85. Sinovac Company Information Table 86. Sinovac Business Overview Table 87. Sinovac Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sinovac Pneumococcal Polysaccharide Vaccine Product Portfolio Table 89. Sinovac Recent Development Table 90. Kangtai Bio Company Information Table 91. Kangtai Bio Business Overview Table 92. Kangtai Bio Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Kangtai Bio Pneumococcal Polysaccharide Vaccine Product Portfolio Table 94. Kangtai Bio Recent Development Table 95. Antejin Biotechnology Company Information Table 96. Antejin Biotechnology Business Overview Table 97. Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Product Portfolio Table 99. Antejin Biotechnology Recent Development Table 100. AIM Bio Company Information Table 101. AIM Bio Business Overview Table 102. AIM Bio Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. AIM Bio Pneumococcal Polysaccharide Vaccine Product Portfolio Table 104. AIM Bio Recent Development Table 105. Sanofi Pasteur Company Information Table 106. Sanofi Pasteur Business Overview Table 107. Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Product Portfolio Table 109. Sanofi Pasteur Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Pneumococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer Pneumococcal Polysaccharide Vaccine Product Portfolio Table 114. Pfizer Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Pneumococcal Polysaccharide Vaccine Distributors List Table 118. Pneumococcal Polysaccharide Vaccine Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Pneumococcal Polysaccharide Vaccine Product Image Figure 2. Global Pneumococcal Polysaccharide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Polysaccharide Vaccine Sales (2021-2032) & (Units) Figure 5. Global Pneumococcal Polysaccharide Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PPSV23 Image Figure 10. PCV13 Image Figure 11. Others Image Figure 12. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pneumococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Centers for Disease Control and Prevention Image Figure 20. Others Image Figure 21. Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 22. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pneumococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 28. Global Pneumococcal Polysaccharide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pneumococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pneumococcal Polysaccharide Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pneumococcal Polysaccharide Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • PPSV23
  • PCV13
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Sino Biopharm
  • Zhifei Biological
  • Walvax
  • Merck & Co.
  • Sinovac
  • Kangtai Bio
  • Antejin Biotechnology
  • AIM Bio
  • Sanofi Pasteur
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 Pneumococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 Pneumococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Polysaccharide Vaccine Industry Restraints
3 Pneumococcal Polysaccharide Vaccine Market by Company
  1. 3.1 Global Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal Polysaccharide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumococcal Polysaccharide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pneumococcal Polysaccharide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pneumococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumococcal Polysaccharide Vaccine Company Product Type and Application
  8. 3.8 Global Pneumococcal Polysaccharide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Polysaccharide Vaccine Market by Type
  1. 4.1 Pneumococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 PPSV23
  3. 4.1.2 PCV13
  4. 4.1.3 Others
  5. 4.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type
  6. 4.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type
  10. 4.3.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 Pneumococcal Polysaccharide Vaccine Market by Application
  1. 5.1 Pneumococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application
  6. 5.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application
  10. 5.3.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 Pneumococcal Polysaccharide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumococcal Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pneumococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sino Biopharm
  2. 8.1.1 Sino Biopharm Company Information
  3. 8.1.2 Sino Biopharm Business Overview
  4. 8.1.3 Sino Biopharm Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sino Biopharm Pneumococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 Sino Biopharm Recent Developments
  7. 8.2 Zhifei Biological
  8. 8.2.1 Zhifei Biological Company Information
  9. 8.2.2 Zhifei Biological Business Overview
  10. 8.2.3 Zhifei Biological Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhifei Biological Pneumococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Zhifei Biological Recent Developments
  13. 8.3 Walvax
  14. 8.3.1 Walvax Company Information
  15. 8.3.2 Walvax Business Overview
  16. 8.3.3 Walvax Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Walvax Pneumococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 Walvax Recent Developments
  19. 8.4 Merck & Co.
  20. 8.4.1 Merck & Co. Company Information
  21. 8.4.2 Merck & Co. Business Overview
  22. 8.4.3 Merck & Co. Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co. Pneumococcal Polysaccharide Vaccine Product Portfolio
  24. 8.4.5 Merck & Co. Recent Developments
  25. 8.5 Sinovac
  26. 8.5.1 Sinovac Company Information
  27. 8.5.2 Sinovac Business Overview
  28. 8.5.3 Sinovac Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Pneumococcal Polysaccharide Vaccine Product Portfolio
  30. 8.5.5 Sinovac Recent Developments
  31. 8.6 Kangtai Bio
  32. 8.6.1 Kangtai Bio Company Information
  33. 8.6.2 Kangtai Bio Business Overview
  34. 8.6.3 Kangtai Bio Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kangtai Bio Pneumococcal Polysaccharide Vaccine Product Portfolio
  36. 8.6.5 Kangtai Bio Recent Developments
  37. 8.7 Antejin Biotechnology
  38. 8.7.1 Antejin Biotechnology Company Information
  39. 8.7.2 Antejin Biotechnology Business Overview
  40. 8.7.3 Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Product Portfolio
  42. 8.7.5 Antejin Biotechnology Recent Developments
  43. 8.8 AIM Bio
  44. 8.8.1 AIM Bio Company Information
  45. 8.8.2 AIM Bio Business Overview
  46. 8.8.3 AIM Bio Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AIM Bio Pneumococcal Polysaccharide Vaccine Product Portfolio
  48. 8.8.5 AIM Bio Recent Developments
  49. 8.9 Sanofi Pasteur
  50. 8.9.1 Sanofi Pasteur Company Information
  51. 8.9.2 Sanofi Pasteur Business Overview
  52. 8.9.3 Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Product Portfolio
  54. 8.9.5 Sanofi Pasteur Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Pneumococcal Polysaccharide Vaccine Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Polysaccharide Vaccine Sales Mode & Process
  6. 9.2 Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst